<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Cholesterol homeostasis failure as a unifying cause of synaptic degeneration</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Elsevier BV</publisher>
				<availability status="unknown"><p>Copyright Elsevier BV</p>
				</availability>
				<date type="published" when="2004-12-16">16 December 2004</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Alexei</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
							<email>alexeikoudinov@neurobiologyoflipids.org</email>
						</author>
						<author>
							<persName><forename type="first">Natalia</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Neurobiology of Lipids 1</orgName>
								<address>
									<postBox>P.O. Box 1665</postBox>
									<postCode>76100</postCode>
									<settlement>Rehovot</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Russian Academy of Medical Sciences</orgName>
								<orgName type="institution" key="instit2">Timoshenko St</orgName>
								<address>
									<addrLine>38-27</addrLine>
									<postCode>121359</postCode>
									<settlement>Moscow</settlement>
									<country key="RU">Russia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Neurobiology of Lipids</orgName>
								<address>
									<postBox>P.O. Box 1665</postBox>
									<postCode>76100</postCode>
									<settlement>Rehovot</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Cholesterol homeostasis failure as a unifying cause of synaptic degeneration</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Journal of the Neurological Sciences</title>
						<title level="j" type="abbrev">Journal of the Neurological Sciences</title>
						<idno type="ISSN">0022-510X</idno>
						<imprint>
							<publisher>Elsevier BV</publisher>
							<biblScope unit="volume">229-230</biblScope>
							<biblScope unit="page" from="233" to="240"/>
							<date type="published" when="2004-12-16">16 December 2004</date>
						</imprint>
					</monogr>
					<idno type="MD5">F85D726B442AB39655EE0B03F02BB976</idno>
					<idno type="DOI">10.1016/j.jns.2004.11.036</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Apolipoprotein E</term>
					<term>BACE</term>
					<term>Dementia</term>
					<term>Immunization</term>
					<term>HDL</term>
					<term>Lipid</term>
					<term>Lipoprotein</term>
					<term>Neuron</term>
					<term>Phospholipid</term>
					<term>Secretase</term>
					<term>Synapse</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>We previously showed that fine tuning of neural cholesterol dynamics is essential for basic synapse function, plasticity and behavior. Significant experimental evidence indicates that cholinergic function, ionotropic and metabotropic receptor machinery, excessive tau phosphorylation, the change of amyloid beta (Abeta or Ah) biochemistry, neural oxidative stress reactions, and other features of neurodegeneration also depend on fine tuning of brain cholesterol homeostasis. This evidence suggest that (i) cholesterol homeostasis break is the unifying primary cause of sporadic and familial Alzheimer's disease (AD), neuromuscular diseases (particularly inclusion-body myositis), Niemann-Pick's type C disease and Down syndrome, and (ii) explains the overlap of neurodegenerative hallmarks across the spectrum of neurodegenerative diseases. Provided is evidence-based explanation of why extremely rare (but scientifically popular) cases of AD associated with mutations in amyloid beta protein precursor (APP) and presenilin (PS) genes, are translated into the disorder via membrane cholesterol sensitivity of APP processing by secretases and Ah generation. The reciprocal effect of Ah on cholesterol synthesis, cellular uptake, efflux and esterification is summarized, as well as the potential implication of such biological function for the compensatory Ah-assisted restoration of the synaptic long-term potentiation (LTP) and resulting inability of tackling amyloid to cure AD.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>1. Cholesterol and synaptic plasticity 1.1. Experimental system of acute modulation of hippocampal cholesterol One of the specific aims of our study was to gain basic knowledge on the role of cholesterol in synaptic plasticity. We first used naive albino Wistar rats ex-vivo hippocampal slices for acute modulation of tissue cholesterol dynamics, followed by the study of slices electrophysiology and immunohistochemistry <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2.">Experimental design</head><p>The experimental design included dissection of rat hippocampus, preparation of thin slices (of about 0.5 mm thickness), slices' maintenance in oxygenated artificial cerebrospinal fluid, incubation of slices with model or natural cholesterol acceptors that increase cellular cholesterol efflux thus modeling increased cholesterol dynamics. The above procedures were followed by electrophysiology or immunostaining and immunofluorescent analysis. We also performed detailed analysis of cholesterol efflux summarized below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3.">Biochemical analysis of cholesterol dynamics in slices</head><p>We used HDL3, high-density lipoproteins 3, prepared from normal human cerebrospinal fluid (CSF), and methylh-cyclodextrine. Both are capable to sequester cholesterol 0022-510X/$ -see front matter D 2004 Published by Elsevier B.V. doi:10.1016/j.jns. <ref type="bibr">2004.11.036</ref> in their hydrophobic core thereby greatly enhancing cholesterol removal from cells and modeling increased cholesterol dynamics. Biochemical analysis of the efflux included radioactive labeling of slices with tritiated cholesterol before incubation with cholesterol acceptors. We found that 6 h incubation with HDL3 (4 Ag/ml by protein) or methyl-h-cyclodextrine (5 mM) cause significant efflux of cholesterol, roughly 30% and 70%, respectively <ref type="bibr" target="#b0">[1]</ref>.</p><p>Cyclodextrine was potent to cause significant efflux of 11% hippocampal cholesterol also at lower concentration (2.5 mM) and short 20 min incubation time <ref type="bibr" target="#b0">[1]</ref>. We also analyzed phospholipid efflux by labeling slices with radioactive choline, incorporating mostly into phosphatydilcholine. We found appreciable efflux of 7% hippocampal phospholipids only during 6 h incubation with 5 mM cyclodextrine co-featuring the efflux of 70% hippocampal cholesterol.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.4.">Fluorescent analysis of cholesterol dynamics in slices</head><p>Fluorescent analysis of cholesterol in slices was performed after the staining of sections with cholesterol binding compound filipin. The analysis was focused on two hippocampal fields, CA1 and Dentate gyrus. Control sections with no cholesterol efflux promotion had cell bodies stained with filipin. This staining was also present at 20 min efflux with cyclodextrine, but disappeared after 6 h of cholesterol efflux. The most illustrative were sections of slices subjected to 6 h incubation with 5 mM cyclodextrine. This condition caused the removal of filipin staining of the hippocampal pyramidal and granule cell bodies yielding their appearance as unstained dark strips. The mild cholesterol efflux preserved cell bodies staining but caused no staining of cholesterol in neural cell processes. High magnification zoomed at stratum radiatum of the CA1 showed dark appearance of bno staining patternQ of cholesterol removal in the neurites.</p><p>Second part of this work, published earlier in the FASEB Journal and as letter in Science magazine, included the analysis of electrophysiological properties of slices as presented below <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.5.">Essential role for cholesterol in synaptic plasticity</head><p>We recorded extracellular field evoked postsynaptic potentials (abbreviated as a EPSP) in the hippocampal CA1 stratum radiatum. We found that slices with increased cholesterol dynamics due to cyclodextrine or HDL3 incubation are impaired in input-output (I/O) relation, the chart of EPSP size versus stimulus intensity, and a parameter of basic synaptic function.</p><p>Experimental slices were also impaired in long-term potentiation (LTP) a long-lasting synaptic enhancement that serve a leading experimental system for the synaptic plasticity that underlie learning and memory.</p><p>Cholesterol efflux also increased the magnitude of the paired pulse facilitation (abbreviated as PPF), an efficient test to detect changes within presynaptic terminals, indicating cholesterol-mediated break of the dynamic properties of synaptic transmission and short-term plasticity. These results suggest an essential role for cholesterol in basic synaptic physiology, neurotransmission and in both postsynaptic and presynaptic plasticity mechanisms.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.6.">Cholesterol disbalance causes hippocampal neural degeneration</head><p>We further tested whether impaired hippocampal cholesterol dynamics causes the disruption of normal neuronal cytoskeleton composed of longitudinally arranged neurofilaments and microtubules. We found that cholesterol depletion causes neurodegenerative fragmentation and teardrop varicose widenings of neurites in all hippocampal subfields and the development of paired helical filaments (PHF) of microtubule-associated protein tau in neurofibrillary tangles (NFT) in the terminal sector of the hippocampal mossy fibers.</p><p>Specifically, acute experimental cholesterol dynamics break caused tau immunostaining of pyramidal and granule cells of the CA1 and the Dentate Gyrus. We also observed the removal of tau-1 staining. Tau-1 is a monoclonal antibody to all electrophoretic forms of non-phosphorylated rat tau, so, no staining with tau-1 indicated phosphorylation of tau-1 epitopes. This was confirmed by immunostaining of experimental slices with AT8 monoclonal antibodies that recognize PHF-tau phosphatase-sensitive epitope (containing phosphorylated Ser-202 residue) and do not recognize normal tau <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>. Cholesterol-dependent PHF-like tau phosphorylation in neuronal cell cultures was shown before <ref type="bibr" target="#b2">[3]</ref>.</p><p>Paired helical filaments, PHF, are abnormal filaments. A decade ago they were proposed by Professor George Perry et al. to substitute normal neurofilaments in the process of neurodegeneration <ref type="bibr" target="#b3">[4]</ref>. To study whether tau phosphorylation is accompanied by a neurofilament change in our experimental system, we performed staining of slices with anti-neurofilament antibody. We found that cholesterol removal with cyclodextrine caused neurodegenerative break of the neurofilament integrity, expressing typical for neurodegeneration neurofilament antibody-positive fragmentations and tea-drop varicose widenings of neural processes in all subfields of the hippocampus.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Cholesterol, other lipids, synaptic plasticity, AB and Alzheimer's disease</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Cholesterol imperfection and amyloid beta protein</head><p>We also performed immunostaining of slices with 4G8 monoclonal antibodies that specifically stain amyloid beta (Ah) protein, the most blamed molecule in Alzheimer's disease research. Under the condition of acute cholesterol modulation with cyclodextrine or HDL3 we did not observe the change in the pattern of Ah immunostaining. The change of Ah chemistry was observed, however, under the condition of chronic cholesterol modulation in vivo. This was shown in rabbits by Sparks <ref type="bibr" target="#b4">[5]</ref>, in transgenic mice by Refolo et al. <ref type="bibr" target="#b5">[6]</ref>, and by us in laboratory rats fed a 2% cholesterol diet for a prolonged period of time, 4 months or longer <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Chronic modulation of cholesterol causes neurodegeneration features</head><p>Cholesterol-fed and control rats were subjected to the analysis of lipid synthesis, study of the synaptic plasticity (LTP), and the histochemical analysis of hamyloid. We also studied the behavior of these animals. We reported cholesterol diet-born changes of rat behavior elsewhere <ref type="bibr" target="#b8">[9]</ref>. Lipid synthesis was studied by incorporation of radioactive [C 14 ]-acetate (a precursor label to trace lipid synthesis) into the newly synthesized lipids. Radioactive cholesterol and phospholipids were further separated by the thin-layer chromatography (TLC), and counted for radioactivity. We found that rats fed a 2% cholesterol diet have increased synthesis of cholesterol and all tested phospholipids (phosphatidylcholine, PC; phosphatidylethanolamine, PE; phosphatidylserine, PS; phosphatidylinositol, PI) in the hippocampus and cortex.</p><p>Electrophysiological analysis of the synaptic plasticity revealed an impairment of the LTP in the cholesterol-fed animals. LTP break could be reversed by the reversal of the diet to the regular one for a prolonged period of time. Most significant, we found a spectrum of amyloid deposits in cholesterol-fed animals. We observed typical Alzheimer's like plaque amyloid, non-mature plaque missing the dense central core, and vascular amyloid deposits. It is important to note that acute modulation of cholesterol (see above) did not affect Ah but featured synaptic plasticity impairment. This is the reason we believe that the change of Ah neurobiochemistry in AD is a secondary compensatory event, not the disease cause.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">LTP and Ab increase hippocampal lipid synthesis, Ab mediates increase of the cholesterol uptake by the hippocampus</head><p>In a separate experimental series we set to test and confirmed that LTP requires neuronal lipid synthesis <ref type="bibr" target="#b0">[1]</ref>. To this end we metabolically labeled slices with radioactive lipid precursor [ 14 C] acetate after the the induction of the LTP with a tetanic stimulus (100 Hz, 1 s). The slices were then washed out of precursor excess, dried on a slide, and incubated with the photographic film to yield radioautograph. Autoradiography revealed the increase in label incorporation into the hippocampal CA1 area after the induction of LTP in stratum radiatum recording pathway as compared with not-tetanized slices subjected to baseline recording only.</p><p>This led us to further test lipid synthesis in hippocampal slices after high potassium (K + )-evoked depolarization, and lipid synthesis modulation by the synthetic analog of amyloid h protein, peptide Ah1-40 <ref type="bibr" target="#b0">[1]</ref>. Over the prolonged incubation with the label slices remained viable and actively synthesized PC, PE, PS and cholesterol. Ah treatment increased the synthesis of PC, PE and cholesterol on 33%, 67% and 46% above the control values (100%), respectively. Additional experimentation showed that Ah also enhanced the uptake of tritiated [ 3 H] cholesterol by slices, ~32.5% in 6 h above the control value (100%, no Ah). In contrast, K + -evoked depolarization did not significantly change specified lipid syntheses, suggesting that membrane depolarization, basal synaptic activity and neurotransmission do not enhance hippocampal lipid synthesis as it occurs after long-lasting synaptic enhancement (LTP).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Amyloid precursor protein (APP) and Ab protein are integrated sensor-effector system for neural cholesterol and membrane dynamics regulation</head><p>Function for Ah in cholesterol and other lipid metabolism and the data on the importance of cholesterol compartmentation for Ah generation indicate feedback functional relation between cholesterol and Ah homeostasis <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b11">11]</ref>. It is supported by a dependency of APP processing by secretases and Ah production on membrane lipid rafts, caveolae, LRP, apoE, cholesterol intracellular storage, sterol regulatory binding protein (SREBP) signaling (particularly on the deficiency in site 2 processing of SREBP and associated inability of cells to upregulate enzymes and proteins involved in cholesterol synthesis and turnover). APP processing and Ah generation also depend on transit of cholesterol via efflux, intracellular trafficking, uptake and its receptor machinery <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b11">11]</ref>. On the other hand, as reported previously, Ah itself affects the key steps of cholesterol homeostasis including cellular uptake, efflux, esterification and synthesis. The latter effect is different in liver, and thus is tissue specific <ref type="bibr" target="#b12">[12,</ref><ref type="bibr" target="#b13">13]</ref>. While the above complex relation is of major importance for normal synaptic function, plasticity (activity-dependent, developmental and under recovery from injury), neurodegeneration, and sporadic AD, the functional interaction of APP, Ah and cholesterol also explains genetic predisposition to neurodegeneration in rare familial AD cases having APP or presenilin (PS) mutations, and in Down syndrome, a trisomy 21 (see below). Please note that PS also depends on cholesterol trafficking and itself affects lipid metabolism <ref type="bibr" target="#b14">[14,</ref><ref type="bibr" target="#b15">15]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Cholesterol and other neurodegenerative diseases</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Cholesterol and neurodegeneration hallmarks</head><p>In fact, significant experimental evidence (that we attempted to integrate in our earlier contribution <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>) show that cholesterol may be the primary cause for a number of neurodegeneration features in general, and in AD in particular (Fig. <ref type="figure" target="#fig_0">1</ref>). These features include, but are not limited to, the discussed above change in tau biology and other cytoskeleton rearrangements, the change in oxidative stress reactions <ref type="bibr" target="#b16">[16]</ref><ref type="bibr" target="#b17">[17]</ref><ref type="bibr" target="#b18">[18]</ref>, and cholinergic dysfunction <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>.</p><p>We believe that in the early phase of AD onset these changes serve important compensatory function. This mean that when due to cholesterol failure synaptic machinery breaks, tau, oxidative reactions and Ah may serve to counterbalance cholesterol homeostasis break, to adapt the brain and help to restore the function. Tau phosphorylation may help re-organize cytoskeleton so, it could appropriately serve neurotransmission. Oxidative reactions could affect membrane lipid peroxidation and modulate synaptic membrane fluidity (critical for receptor function) so the neurotransmission receptor machinery remains functional. Ah may serve to modulate oxidative cascade reactions, because Ah normally serves as antioxidant <ref type="bibr" target="#b16">[16]</ref>. We showed that Ah can also modulate lipid synthesis, cholesterol and phospholipids in particular, and thus help to restore neural dynamics of these pivotal lipid membrane components.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Overlap of neurodegeneration hallmarks across the spectrum of neurodegenerative diseases</head><p>It is important to realize that different neurodegenerative diseases express significant overlap in major markers. Some Fig. <ref type="figure" target="#fig_0">1</ref>. Neurodegeneration hallmarks: brain disease endpoints or reversible compensatory mechanisms designed by nature? The scheme illustrates the genesis of cholesterol-mediated neurodegeneration. Although the scheme was originally developed to represent the cascade of the sporadic forms of Alzheimer's disease (see detailed original legend for the scheme at http://neurobiologyoflipids.org/content/1/6 <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>) it is applicable with no modification to other nervous system pathologies described at length of this article as disorders of cholesterol-mediated neurodegeneration (A). The scheme, however, is also applied to other neurodegenerative brain diseases. This is because in response on the central event of any type neurodegeneration, an Impairment of neurotransmission, synaptic function and plasticity (B), CNS launches standard set of physiological compensatory mechanisms that aim to restore impaired synaptic function (C, ticks). Primary cause of a disease (that in case of Parkinson's disease may be the failure of the forebrain dopamine system, for example) defines the specificity of a chemical neurotransmission break, and the fine tuning of compensatory mechanisms and their combination (C), yielding the unique pattern of neurodegenerative markers overlap in different diseases <ref type="bibr" target="#b19">[19,</ref><ref type="bibr" target="#b20">20]</ref> and individual patients <ref type="bibr" target="#b30">[30]</ref>. Such look on neurodegeneration requires novel focus for drug therapy: a restoration of impaired primary cause that will lead to the reversal of a disease secondary features. The proposed scenario implies that battling secondary degenerative features sadly has no ability to cure any type neurodegeneration. This figure is adapted and used by permission <ref type="bibr" target="#b6">[7]</ref>.</p><p>of these features are also present normally during specific period of ontogenesis, further implying that what we call bpathogenesis markersQ are in fact tested by nature developmental or compensatory mechanisms. This means that fighting the conventional disease features, Ah and tau for example, will not benefit patients as underlying primary cause will not be cured. But what is a primary neurodegeneration cause?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">What is a primary cause for neurodegeneration?</head><p>Is there a relevance of cholesterol mediated neurodegeneration to different neurodegenerative diseases? If so is there neurodegeneration specificity? We do think so. We believe that cholesterol dynamics failure may be a primary pathogenic cause in a number of diseases, such as AD, Down syndrome, neuromuscular disorders, and of course Niemann-Pick's type C disease. On the other hand other diseases may have another primary pathological break (e.g. the break of the forebrain dopamine system in Parkinson's disease). Even in this case the brain may operate its standard set of compensatory mechanisms, causing the overlap of morphologic changes, and explaining the unity of markers across the spectrum of neurodegenerative disorders (Fig. <ref type="figure" target="#fig_0">1</ref>) <ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref><ref type="bibr" target="#b21">[21]</ref><ref type="bibr" target="#b22">[22]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Cholesterol and Down syndrome</head><p>Down syndrome patients are characterized by reduced cholesterol esterification in plasma <ref type="bibr" target="#b23">[23]</ref>. They also have specific pattern of the liver sterol regulatory element binding protein (SREBP) activation, and sterol-independent maturation of SREBP. Down syndrome is also characterized by high circulating and tissue cholesterol levels in utero <ref type="bibr" target="#b24">[24]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.">Neuromuscular disease, Ab/APP metabolism and cholesterol</head><p>Further investigation is warranted to elucidate the normal role for Ah at synapse and neuro-muscular junctions (NMJ). In a study published a decade ago <ref type="bibr" target="#b25">[25]</ref>, it was first demonstrated that APP and Ah concentrate postsynaptically at human NMJs, leading authors to conclude that bAPP may have a role in normal junction biology and possibly in some diseases affecting NMJsQ. Another study later showed that APP homolog in Drosophila (APPL) promotes synapse differentiation at the neuromuscular junction <ref type="bibr" target="#b26">[26]</ref>, leading the authors to propose a model bby which APPL, in conjunction with activity-dependent mechanisms, regulates synaptic structure and numberQ. Few years later this pivotal knowledge, changing the neuroscience research community view on Ah as solely neurotoxic, was extended with data obtained for the CNS synapses. The latter study showed activity dependent secretion of Ah and proposed roles for Ah in synaptic transmission <ref type="bibr" target="#b27">[27,</ref><ref type="bibr" target="#b28">28]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.6.">Ab, cholesterol and synaptic plasticity: a functional triangle</head><p>In our own recent study peptide Ah1-40 rescued synaptic plasticity, while cholesterol synthesis inhibition with mevinolin (a member of a group of drugs inhibiting cholesterol biosynthesis, HMG-CoA reductase inhibitors, also called statins) abolished the restorative action of the Ah peptide. This observation confirms that Ah protein is a functional player in synaptic structure-functional plasticity on one hand, and in cholesterol neurochemical pathways on the other <ref type="bibr" target="#b11">[11]</ref>.</p><p>The change of Ah biology and PHF tau phosphorylation are characteristic features of inclusion-body myositis (IBM) <ref type="bibr" target="#b29">[29]</ref>. Furthermore, Ah accumulation in cerebral vessels and plaques may be much more general neural degeneration phenomenon then previously thought, as it occurs frequently not only in AD, but also in Parkinson's disease (PD), diffuse Lewy body disease (DLBD), progressive supranuclear palsy (PSP) but not multiple systems atrophy (MSA) or amyotrophic lateral sclerosis (ALS) <ref type="bibr" target="#b30">[30]</ref>. This study, however, reports an unusual ALS case marked by extensive cerebral Ah deposition in small and medium-size vessels, capillaries, and perivascular plaques in the cerebral cortex, and in most leptomeningeal vessels, but lacking cognitive impairment. The authors' conclusion is: bthe lack of cognitive impairment in the case presented argues against the idea that extensive amyloid h deposition in the brain causes dementiaQ <ref type="bibr" target="#b30">[30]</ref>.</p><p>Finally, most recent study showed an abnormal accumulation of lipoprotein receptors (including LDL-R receptor, VLDL-R receptor, and lipoprotein related protein, LRP) and cholesterol in vacuolated muscle fibers in IBM <ref type="bibr" target="#b29">[29]</ref>. In ball myopathies, a subset of regenerating and necrotizing muscle fibers had prominent diffuse accumulation of both LDL-R and cholesterolQ <ref type="bibr" target="#b29">[29]</ref>. Lipoprotein receptors govern cellular uptake of cholesterol in its receptor-mediated transport <ref type="bibr" target="#b31">[31]</ref>. What is their role in neurodegenerative diseases and how this is related to cholesterol and synapse normal dynamics and pathological failure remains to be investigated. The detection of lipoprotein receptors at normal NMJ postsynaptically <ref type="bibr" target="#b29">[29]</ref> and their abundance in the hippocampus <ref type="bibr" target="#b0">[1]</ref> suggests their physiological role for neurotransmission in both peripheral and central nervous system. Explaining our own data (see section bEssential role for cholesterol in synaptic plasticityQ above) and integrating them with important studies by others <ref type="bibr" target="#b32">[32,</ref><ref type="bibr" target="#b33">33]</ref> we proposed in 2001 that lipoprotein receptormediated cholesterol redistribution and synthesis could be adaptive complementary processes important at early and late stages of the activity-dependent synaptic structurefunction plasticity that underlie learning and memory <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b34">34]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.7.">Apolipoprotein E, cholesterol and neuromuscular diseases</head><p>Apolipoprotein (apo) E is known as a major genetic AD risk factor <ref type="bibr" target="#b35">[35]</ref>. Less appreciated in neurology is the central role for apoE in cholesterol metabolism, as it serves as a major cholesterol transport apolipoprotein. ApoE involvement in AD may be mediated through cholesterol dynamics <ref type="bibr" target="#b35">[35]</ref>. Recent review on the subject summarized that apoE may be important in neuromuscular disease in the same way as in Alzheimer's, q4 allele serving a bad allele, and q2 being a protective one bagainst developing certain neuromuscular diseases, including the ALS/Parkinsonism/dementia complex of Guam. This allele is also associated with a better prognosis in neuromuscular diseases such as motor neuron disease. The effect of various APOE alleles on neuromuscular diseases therefore parallels their influence on CNS diseasesQ, the authors conclude <ref type="bibr" target="#b36">[36]</ref>. ApoE q4 homozygosity may also accelerate tau phosphorylation and NFT formation and Ah deposition in Niemann-Pick type C disease <ref type="bibr" target="#b37">[37]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.8.">Niemann-Pick type C disease, cholesterol and neurodegeneration</head><p>Niemann-Pick disease type C (NPC) bis an inherited neurodegenerative disorder associated with intracellular cholesterol and glycolipid trafficking defects. Two separate genes, NPC1 and NPC2, have been linked to NP-C. NPC1 encodes a polytopic membrane-bound protein with a putative sterol-sensing domain. NPC2 has been recently identified as epididymal secretory glycoprotein 1. The NPC1 protein functions in the vesicular redistribution of endocytosed lysosomal cargoQ <ref type="bibr" target="#b38">[38]</ref>, and is a key component in the intracellular distribution of cholesterol obtained from lipoproteins by the endocytic pathway. A mouse model of Niemann-Pick type C disease bexhibits neuropathology similar to the human condition. There is an age-related neurodegeneration in several brain regions and a lack of myelin in the corpus callosumQ <ref type="bibr" target="#b39">[39]</ref>.</p><p>One of the explanations bsuggest that a functional disturbance in NPC1 could disrupt vesicular transport of cholesterol, glycolipids and possibly other endocytic cargo in glia, which is critical for maintaining the integrity of neurons <ref type="bibr" target="#b38">[38,</ref><ref type="bibr" target="#b39">39]</ref>. The view of NPC neurodegeneration as a pathology of neuronal cholesterol proper was also suggested <ref type="bibr" target="#b40">[40]</ref>. bUsing filipin fluorometry of neuronal cells in tissue slices, [authors] found massive accumulation of cholesterol in neurons in four out of five human NPC cases. Neurofibrillary tangles composed of aggregates of the otherwise highly soluble protein tau were present in three Niemann-Pick type C cases and were also immunologically identical to those associated with ADQ <ref type="bibr" target="#b40">[40]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Specificity of cholesterol-mediated neurodegeneration</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.">Cholesterol, neurodegeneration and neurotransmission chemical specifity</head><p>Another important question is: what is the specific mechanism of cholesterol-mediated synaptic function break? Recent and emerging evidence shows that cholestrol affects the pharmacology of the several chemical neurotransmitters, receptor and transporter systems, including cholinergic <ref type="bibr" target="#b41">[41]</ref><ref type="bibr" target="#b42">[42]</ref><ref type="bibr" target="#b43">[43]</ref>, GABAergic <ref type="bibr" target="#b44">[44]</ref><ref type="bibr" target="#b45">[45]</ref><ref type="bibr" target="#b46">[46]</ref>, 5-HT1A/serotonin <ref type="bibr" target="#b47">[47,</ref><ref type="bibr" target="#b48">48]</ref>, inhibitory glycine <ref type="bibr" target="#b49">[49]</ref> and excitatory amino acid systems <ref type="bibr" target="#b50">[50]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.">Cholesterol and the nicotinic acetylcholine receptors (nAChR)</head><p>Perhaps, the most advanced data are available for the nicotinic acetylcholine receptors (nAChR). The isolated nAChRs express high affinity for cholesterol. Cholesterol is also required for functional insertion of nAChRs into artificial membranes: bonly after nAChRs are inserted into the postsynaptic membrane and charged with cholesterol do they become fully activeQ <ref type="bibr" target="#b41">[41]</ref><ref type="bibr" target="#b42">[42]</ref><ref type="bibr" target="#b43">[43]</ref>. There are several proposed mechanisms <ref type="bibr" target="#b41">[41]</ref>, but the details remain to be investigated. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusions</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>1 .</head><label>1</label><figDesc>Cholesterol itself plays an essential role in synaptic function, plasticity and neurodegeneration. 2. The failure of fine tuning of brain cholesterol homeostasis causes the change of cholinergic function, ionotropic and metabotropic receptor machinery, excessive tau phosphorylation, modulates Ah biochemistry, neural oxidative stress reactions, and other features of neurodegeneration. The above changes are secondary features representing functional compensation for neural cholesterol biological misregulation. 3. The above explains the overlap of neurodegenerative hallmarks across the spectrum of neurodegenerative diseases. 4. Cholesterol homeostasis break is the unifying primary cause and the major target for therapy of sporadic and familial AD, neuromuscular diseases, Niemann-Pick's type C disease and Down syndrome.</figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0">A.R.Koudinov, N.V. Koudinova / Journal of the Neurological Sciences 229 -230 (2005) 233-240</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p>This article serves to commemorate the 40th anniversary of the BioMedical Faculty of the Russian State Medical University (November 2003), the authors' alma mater. Our research is dedicated to our parents and our kids.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Essential role for cholesterol in synaptic plasticity and neuronal degeneration</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/1/6/neurolipids112002-02.html#fr1" />
	</analytic>
	<monogr>
		<title level="j">FASEB J</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1858" to="1860" />
			<date type="published" when="2001-06-27">2001. June 27, 2001</date>
		</imprint>
	</monogr>
	<note>Also available as slide</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Cholesterols&apos; role in synapse formation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">295</biblScope>
			<biblScope unit="page">2213</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cholesteroldependent modulation of tau phosphorylation in cultured neurons</title>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">W</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Senda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yanagisawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Michikawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="391" to="400" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Neuropil threads of Alzheimer&apos;s disease show a marked alteration of the normal cytoskeleton</title>
		<author>
			<persName><forename type="first">G</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kawai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tabaton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1748" to="1755" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Sparks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="88" to="94" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Hypercholesterolemia accelerates the Alzheimer&apos;s amyloid pathology in a transgenic mouse model</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Refolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pappolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Malester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Dis</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="321" to="331" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Brain cholesterol pathology is the cause of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
		<ptr target="http://clinmed.netprints.org/cgi/content/full/2001100005v1" />
	</analytic>
	<monogr>
		<title level="j">Clin Med Health Res. Published online</title>
		<imprint>
			<date type="published" when="2001-11-27">Nov 27, 2001, clinmed/2001100005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Cholesterol, synaptic function and Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacopsychiatry</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="107" to="112" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Dietary cholesterol impairs behavior of lab rats with naive genotype: evidence for the sufficiency of the environmental brain cholesterol modulation to cause sporadic Alzheimer&apos;s neurodegeneration phenotype</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/2/3/" />
	</analytic>
	<monogr>
		<title level="j">Soc Neurosci Abstr. Program No</title>
		<imprint>
			<biblScope unit="volume">730</biblScope>
			<biblScope unit="issue">3</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Neurobiol Lipids</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">APP and amyloid beta protein are integrated sensor-effector system for neural cholesterol and membrane dynamics regulation</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Soc Neurosci Abstr. Program No</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">8</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title/>
		<ptr target="http://neurobiologyoflipids.org/content/2/3/" />
	</analytic>
	<monogr>
		<title level="j">Neurobiol Lipids</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">3</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Amyloid beta protein restores hippocampal long term potentiation: a central role for cholesterol?</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/1/8/" />
	</analytic>
	<monogr>
		<title level="j">Neurobiol Lipids</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">8</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Multiple inhibitory effects of Alzheimer&apos;s peptide Abeta1-40 on lipid biosynthesis in HepG2 cells</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Berezov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">395</biblScope>
			<biblScope unit="page" from="204" to="206" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Alzheimer&apos;s Ah1-40 peptide modulates lipid synthesis in neuronal cultures and intact rat fetal brain under normoxic and oxidative stress conditions</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Yavin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurochem Res</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="653" to="660" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Presenilin function regulates Niemann-Pick C1 protein levels</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mackenzie</forename><surname>Ingano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kovacs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/2/3/" />
	</analytic>
	<monogr>
		<title level="j">Soc Neurosci Abstr</title>
		<imprint/>
	</monogr>
	<note>Program No. 729.5 Neurobiol Lipids. 2, 3. Available at</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Presenilin is essential for cellular lipid homeostasis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grimm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Paetzhold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Grimm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ruppert</surname></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/2/3/" />
	</analytic>
	<monogr>
		<title level="j">Soc Neurosci Abstr. Program No</title>
		<imprint>
			<biblScope unit="volume">666</biblScope>
		</imprint>
	</monogr>
	<note>3 Neurobiol Lipids. 2, 3. Available at</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Amyloid-beta as a lipid antioxidant: how excess becomes damaging</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kontush</surname></persName>
		</author>
		<idno>145.00. 3rd</idno>
		<ptr target="http://neurobiologyoflipids.org/symposia" />
	</analytic>
	<monogr>
		<title level="m">International congress on vascular dementia</title>
				<meeting><address><addrLine>Prague, Czech Republic</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2003">Oct. 25 2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Amyloid beta, neural lipids, cholesterol and Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kontush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Berezov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/1/6/" />
	</analytic>
	<monogr>
		<title level="j">Neurobiol Lipids</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">6</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Resistance of human cerebrospinal fluid to in vitro oxidation is directly related to its amyloid-beta content</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kontush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Donarski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Beisiegel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Free Radic Res</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="507" to="517" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Beware the simplification in defining neurodegenerative diseases</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
		<ptr target="http://bmj.com/cgi/eletters/324/7352/1465#23278" />
	</analytic>
	<monogr>
		<title level="j">BMJ online</title>
		<imprint>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Is neurodegeneration a unique multifarious human brain disease?</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
		<ptr target="http://bmj.bmjjournals.com/cgi/eletters/324/7352/1465#23308" />
	</analytic>
	<monogr>
		<title level="j">Br Med J</title>
		<imprint>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Prospects for new restorative and neuroprotective treatments in Parkinson disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Dunnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bjorklund</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Neurol Disord</title>
		<imprint>
			<biblScope unit="volume">399</biblScope>
			<biblScope unit="page" from="A32" to="39" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Symposium abstracts: cholesterol and Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Michikawa</surname></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/1/4" />
	</analytic>
	<monogr>
		<title level="j">Neurobiol Lipids</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">4</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Lecithin: cholesterol acyltransferase in Down&apos;s syndrome</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Lacko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Hayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Mcconathy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lacko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Redheendran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chim Acta</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="133" to="141" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Alteration of SREBP activation in liver of Trisomy 21 fetuses</title>
		<author>
			<persName><forename type="first">L</forename><surname>Diomede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Salmona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Albani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">260</biblScope>
			<biblScope unit="page" from="499" to="503" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Strong immunoreactivity of betaamyloid precursor protein, including the beta-amyloid protein sequence, at human neuromuscular junctions</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="96" to="100" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The Drosophila beta-amyloid precursor protein homolog promotes synapse differentiation at the neuromuscular junction</title>
		<author>
			<persName><forename type="first">L</forename><surname>Torroja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Packard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gorczyca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Budnik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="7793" to="7803" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Activity dependent secretion of h-amyloid: roles of hamyloid in synaptic transmission</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Kamenetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tomita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Borchelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Sisodia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Iwatsubo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Malinow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Abstr-Soc Neurosci</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page">491</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">APP processing and synaptic function</title>
		<author>
			<persName><forename type="first">F</forename><surname>Kamenetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tomita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hsieh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="925" to="937" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle</title>
		<author>
			<persName><forename type="first">M</forename><surname>Jaworska-Wilczynska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Wilczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Strickland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Weisgraber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="438" to="445" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Brain Accumulation of amyloid-beta in non-Alzheimer neurodegeneration</title>
		<author>
			<persName><forename type="first">J</forename><surname>Primavera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">X</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Riskind</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Iulian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">La</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Monte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Alzheimer&apos;s Dis</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="183" to="193" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Cholesterol homeostasis failure at neuromuscular junctions and CNS synapses: a unifying cause of synaptic degeneration?</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Natalia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Koudinova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Beisiegel</surname></persName>
		</author>
		<ptr target="http://www.neurology.org/cgi/eletters/58/3/438#263" />
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zhuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Holtzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Osaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Demaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jacquin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="542" to="549" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Inhibition by compactin demonstrates a requirement of isoprenoid metabolism for long-term potentiation in rat hippocampal slices</title>
		<author>
			<persName><forename type="first">H</forename><surname>Matthies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hollt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krug</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="341" to="346" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">A link between cholesterol, CNS, synapse and brain diseases: is there a need for a reinvention?</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Koudinov</surname></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/2/1/" />
	</analytic>
	<monogr>
		<title level="j">Neurobiol Lipids</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">The role of apoE in Alzheimer&apos;s disease: an alternative view: live discussion held on 11</title>
		<ptr target="http://www.alzforum.org/res/for/journal/crutcher/crutcher_transcript.asp" />
	</analytic>
	<monogr>
		<title level="j">Alzh Res Forum</title>
		<imprint>
			<date type="published" when="2001-12">Dec 2001. 2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Apolipoprotein E and neuromuscular disease: a critical review of the literature</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Bedlack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Strittmatter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Morgenlander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1561" to="1565" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Nanba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ohno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Murayama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="351" to="355" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Neurodegeneration in Niemann-Pick type C disease mice</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Ong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Switzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sidhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Suresh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Brain Res</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="218" to="231" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Neurodegeneration in the Niemann-Pick C mouse: glial involvement</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>German</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Yazdani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Dietschy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroscience</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="437" to="450" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain</title>
		<author>
			<persName><forename type="first">R</forename><surname>Distl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Treiber-Held</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Albert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Meske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Harzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Ohm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pathol</title>
		<imprint>
			<biblScope unit="volume">200</biblScope>
			<biblScope unit="page" from="104" to="111" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist</title>
		<author>
			<persName><forename type="first">M</forename><surname>Naguib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Flood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Mcardle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Brenner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anesthesiology</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="202" to="231" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">The effect of cholesterol on agonist-induced flux in reconstituted acetylcholine receptor vesicles</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Dalziel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Rollins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Mcnamee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="193" to="196" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Effects of 20,25-diazacholesterol treatment on the decay of end-plate currents</title>
		<author>
			<persName><forename type="first">D'</forename><surname>Alonzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Mcardle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="681" to="683" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Influence of membrane cholesterol on modulation of the GABA(A) receptor by neuroactive steroids and other potentiators</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sooksawate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Simmonds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="1303" to="1311" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Effects of membrane cholesterol on the sensitivity of the GABA A receptor to GABA in acutely dissociated rat hippocampal neurones</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sooksawate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Simmonds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="178" to="184" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">The emerging neurobiology of cholesterol</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Simmonds</surname></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/1/1/" />
	</analytic>
	<monogr>
		<title level="j">Neurobiol Lipids</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Membrane cholesterol modulates serotonin transporter activity</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Scanlon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schloss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochemistry</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="10507" to="10513" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">HT1A receptor-mediated ERK activation, but not adenylyl cyclase inhibition, is sensitive to membrane cholesterol depletion</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Scalzitti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Holstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Jeske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Clarke</forename><forename type="middle">W</forename></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/2/3/" />
	</analytic>
	<monogr>
		<title level="j">Soc Neurosci Abstr. Program No</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="issue">3</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Neurobiol Lipids</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Membrane cholesterol affects the pharmacology of the recombinant inhibitory glycine receptor</title>
		<author>
			<persName><forename type="first">B</forename><surname>Laube</surname></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/2/3/" />
	</analytic>
	<monogr>
		<title level="j">Soc Neurosci Abstr. Program No</title>
		<imprint>
			<biblScope unit="volume">797</biblScope>
			<date>10</date>
		</imprint>
	</monogr>
	<note>Neurobiol. Lipids.</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">The association of excitatory amino acid transporters and their interacting proteins with cholesterol-rich microdomains of the plasma membrane</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Butchbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-Ig</forename><surname>Lin</surname></persName>
		</author>
		<ptr target="http://neurobiologyoflipids.org/content/2/3/" />
	</analytic>
	<monogr>
		<title level="j">Soc Neurosci Abstr. Program No</title>
		<imprint>
			<biblScope unit="volume">254</biblScope>
			<biblScope unit="issue">10</biblScope>
		</imprint>
	</monogr>
	<note>Neurobiol Lipids</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
